Breaking News
Global News
Chola Securities in News
Sessions News
Economy News
Nifty 50
Sensex
Nifty Bank
Bankex
Nifty 100
BSE Sensex 50
Nifty Financial Services
BSE Sensex Next 50
Nifty Midcap 100
BSE Bharat 22
Nasdaq
DJIA
S&P 500
Hang Seng
Nikkei 225
Straits Times
FTSE 100
KLSE Composite
Jakarta Composite
Exchange Holiday List
Historical Returns
Top Gainers
Top Losers
52 Week High
52 Week Low
Most Active by Value
Most Active by Volume
Out Performer
Under Performer
Advances & Declines
Only Buyers and Sellers
Bulk deal
Block deal
Nifty Futures
Nifty Options
Bank Nifty Futures
Bank Nifty Options
Stock Futures
Stock Options
Increase in OI
Decrease in OI
Highest in OI
Lowest in OI
All Index Futures
Most Active Contracts
Most Active Call
Most Active Put
Solutions
Platforms
Research
More
Markets
Become a partner
Revenue from operations rose 35.81% YoY to Rs 157.11 crore in the quarter ended 31 March 2026.
On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26.
Profit before tax stood at Rs 31.67 crore in Q4 FY26, up 66.07% year-on-year and up 36.68% quarter-on-quarter.
EBITDA jumped 50.38% to Rs 38.8 crore in the March quarter, compared with Rs 25.8 crore a year earlier. EBITDA margin improved to 24.6% from 22% in the corresponding period last year.
For the full financial year FY26, the company reported a 69% surge in consolidated net profit to Rs 67.35 crore, while revenue from operations rose 35.89% to Rs 503.08 crore.
Net cash used in operating activities stood at Rs 16.59 crore in FY26 compared with positive operating cash flow of Rs 52.72 crore in FY25.
Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products.
Powered by Capital Market - Live News
on Chola Securities Mobile & Web App.
Stay organised, informed & in control while accessing your portfolio, reports, trading tools and service requests—all in one seamless platform.